Trovagene (TROV) Announces PLK1 Inhibitor (PCM-075) Demonstrates Synergy with Zytiga (abiraterone acetate)
Tweet Send to a Friend
Trovagene, Inc. (NASDAQ: TROV) today announced positive data from preclinical research demonstrating synergy of PCM-075, its oral, highly-selective Polo-like ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
